Acurx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own20.60% Shs Outstand10.23M Perf Week-13.57%
Market Cap24.93M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float7.87M Perf Month-39.50%
Income-13.90M PEG- EPS next Q-0.35 Inst Own3.10% Short Float0.45% Perf Quarter-33.15%
Sales- P/S- EPS this Y-209.80% Inst Trans287.97% Short Ratio2.00 Perf Half Y-47.96%
Book/sh1.04 P/B2.33 EPS next Y0.80% ROA-97.80% Target Price12.00 Perf Year-
Cash/sh1.08 P/C2.25 EPS next 5Y- ROE-105.40% 52W Range2.33 - 8.74 Perf YTD-44.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.40% Beta-
Dividend %- Quick Ratio17.90 Sales past 5Y- Gross Margin- 52W Low7.30% ATR0.27
Employees3 Current Ratio17.90 Sales Q/Q- Oper. Margin- RSI (14)30.86 Volatility8.55% 8.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-68.90% Profit Margin- Rel Volume0.23 Prev Close2.42
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume17.62K Price2.50
Recom2.00 SMA20-21.67% SMA50-27.87% SMA200-41.49% Volume3,936 Change3.31%
May-11-22 07:01AM  
Apr-29-22 08:01AM  
Mar-24-22 03:23PM  
Mar-17-22 07:01AM  
Mar-16-22 08:01AM  
Mar-07-22 08:01AM  
Feb-07-22 08:01AM  
Dec-06-21 08:01AM  
Nov-12-21 06:01PM  
Nov-08-21 08:01AM  
Nov-01-21 08:01AM  
Oct-27-21 08:01AM  
Oct-04-21 09:00AM  
Sep-30-21 08:00AM  
Sep-29-21 08:00AM  
Sep-27-21 08:00AM  
Sep-25-21 08:02AM  
Sep-13-21 08:03AM  
Sep-02-21 08:00AM  
Aug-31-21 08:00AM  
Aug-17-21 07:00AM  
Aug-16-21 04:05PM  
Aug-12-21 08:00AM  
Aug-05-21 08:00AM  
Aug-02-21 08:00AM  
Jul-28-21 08:00AM  
Jul-07-21 09:00AM  
Jul-01-21 08:00AM  
Jun-29-21 04:01PM  
Jun-25-21 01:23PM  
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sailer CarlDirectorNov 23Buy4.845,16124,97973,078Nov 24 04:06 PM
LUCI DAVID PPresident and CEONov 19Buy4.805,20024,9601,008,723Nov 22 04:05 PM
DELUCCIA ROBERT JDirectorNov 19Buy4.905,03424,6721,031,461Nov 22 04:05 PM
Sailer CarlDirectorJun 29Buy6.0012,50075,00067,917Sep 10 04:16 PM